Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.80 |
| ▸ | HTT | P42858 | 2/20 | 0.77 |
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.70 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.50 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.50 |
| ▸ | LPAR2 | Q9HBW0 | 4/20 | 0.50 |
| ▸ | LPAR6 | P43657 | 3/20 | 0.50 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1834847 | 1.00 | USP2 (0.80) | USP2HTTLPAR5SPHK1CYP1A2 | |
| SCHEMBL2996593 | 1.00 | USP2 (0.80) | USP2HTTLPAR5SPHK1CYP1A2 | |
| SCHEMBL10607854 | 1.00 | USP2 (0.80) | USP2HTTLPAR5SPHK1CYP1A2 | |
| SCHEMBL10566561 | 1.00 | USP2 (0.80) | USP2HTTLPAR5SPHK1CYP1A2 | |
| SCHEMBL10605202 | 1.00 | USP2 (0.80) | USP2HTTLPAR5SPHK1CYP1A2 | |
| SCHEMBL8527626 | 1.00 | USP2 (0.80) | USP2HTTLPAR5SPHK1CYP1A2 | |
| SCHEMBL1835536 | 1.00 | USP2 (0.80) | USP2HTTLPAR5SPHK1CYP1A2 | |
| SCHEMBL9117095 | 1.00 | USP2 (0.80) | USP2HTTLPAR5SPHK1CYP1A2 | |
| SCHEMBL2853658 | 1.00 | USP2 (0.80) | USP2HTTLPAR5SPHK1CYP1A2 | |
| SCHEMBL28914358 | 1.00 | USP2 (0.80) | USP2HTTLPAR5SPHK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 331 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122029280-A | Oligonucleotide with glycol modification | 马萨诸塞大学 | 2026-05-12 | — | — | CN | disclosed |
| US-20250354148-A1 | DUAL-ACTING siRNA BASED MODULATION OF C9orf72 | UNIV MASSACHUSETTS (US) | 2025-11-20 | — | — | US | disclosed |
| US-12037585-B2 | Oligonucleotides for tissue specific gene expression modulation | UNIVERSITY OF MASSACHUSETTS (US) | 2024-07-16 | — | — | US | disclosed |
| US-12024706-B2 | Modified oligonucleotides targeting SNPs | UNIVERSITY OF MASSACHUSETTS (US) | 2024-07-02 | — | — | US | disclosed |
| WO-2024129710-A1 | CARBOHYDRATE CONJUGATES FOR THE DELIVERY OF THERAPEUTIC OLIGONUCLEOTIDES | UNIVERSITY OF MASSACHUSETTS (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240191230-A1 | CONJUGATES OF SIRNA AND ANTISENSE OLIGONUCLEOTIDES (SIRNASO) AND METHODS OF USE IN GENE SILENCING | UNIVERSITY OF MASSACHUSETTS | 2024-06-13 | — | — | US | disclosed |
| US-20240182904-A1 | OLIGONUCLEOTIDES TARGETING S6K1 | UNIVERSITY OF MASSACHUSETTS | 2024-06-06 | — | — | US | disclosed |
| WO-2024110843-A1 | ENHANCING OLIGONUCLEOTIDE IMMUNOMODULATORY ACTIVITY THROUGH DIANOPHORE LONG-LASTING MODIFICATION: METHODS AND APPLICATIONS | SEGENA CORPORATION S.A. (UY) | 2024-05-30 | — | — | WO | disclosed |
| US-11981892-B2 | Compositions and methods for improved gene editing | UNIVERSITY OF MASSACHUSETTS (US) | 2024-05-14 | — | — | US | disclosed |
| US-20240141362-A1 | MODIFIED OLIGONUCLEOTIDES WITH INCREASED STABILITY | UNIV MASSACHUSETTS (US) | 2024-05-02 | — | — | US | disclosed |
| US-4082678-A | RECEPTACLE RELEASABLY CONTAINING AN AGENT FOR MAKING AN INNER RECEPTACLE WATER INSOLUBLE | THE PROCTER & GAMBLE COMPANY (US) | 1978-04-04 | — | — | US | disclosed |
| US-4081384-A | ANTISTATIC AGENTS, FABRIC SOFTENERS | THE PROCTOR & GAMBLE COMPANY (US) | 1978-03-28 | — | — | US | disclosed |
| US-4077891-A | Fabric treatment compositions | THE PROCTER & GAMBLE COMPANY (US) | 1978-03-07 | — | — | US | disclosed |
| US-4076633-A | Fabric treating articles with improved conditioning properties | THE PROCTER & GAMBLE COMPANY (US) | 1978-02-28 | — | — | US | disclosed |
| US-4073996-A | DRIER CONDITIONER | THE PROCTER & GAMBLE COMPANY (US) | 1978-02-14 | — | — | US | disclosed |
| US-4055248-A | Fabric treating compositions and articles | THE PROCTER & GAMBLE COMPANY (US) | 1977-10-25 | — | — | US | disclosed |
| US-4018688-A | Capsules, process of their preparation and fabric conditioning composition containing said capsules | THE PROCTER & GAMBLE COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
| US-4000340-A | WATER-INSOLUBLE ALCOHOLS, CARBOXYLIC ACIDS, OR SALTS; NONIONIC SURFACTANTS | THE PROCTER & GAMBLE COMPANY (US) | 1976-12-28 | — | — | US | disclosed |
| US-3993741-A | SELENIUM AND TELLURIUM COMPOUNDS; RADIOACTIVE MATERIALS | U.S. PHILIPS CORPORATION (US) | 1976-11-23 | — | — | US | disclosed |
| US-3989631-A | Fabric treating compositions comprising clay mixtures | THE PROCTER & GAMBLE COMPANY (US) | 1976-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182904-A1 | OLIGONUCLEOTIDES TARGETING S6K1 | RPL7A, EEF2K, SRPK1 | USP2 2106/4885HTT 482/4885LPAR5 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.